CNS Pharmaceuticals Appoints Rami Levin as President and CEO to Advance Brain Cancer Pipeline

CNS Pharmaceuticals Inc. has appointed Rami Levin as president and chief executive officer, effective January 1, 2026, following John Climaco's departure from the CEO role. Levin brings nearly three decades of global leadership experience across oncology, neurology and rare diseases to the biopharmaceutical company, which specializes in developing treatments for primary and metastatic cancers of the brain and central nervous system. The leadership transition positions CNS Pharmaceuticals to advance its pipeline and enter its next phase of development, leveraging Levin's track record of advancing late-stage clinical programs, scaling organizations and leading strategic turnarounds.

The company's clinical-stage pipeline includes TPI 287, an abeotaxane drug candidate that stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. Initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat central nervous system tumors. The drug candidate has been tested in over 350 patients across clinical trials as both monotherapy and in combination with bevacizumab for various conditions including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain.

To date, TPI 287 appears to have both an excellent safety profile and high tolerability among patients, according to company data. The leadership change comes as CNS Pharmaceuticals continues developing its anti-cancer drug candidates, with Levin's extensive experience in oncology expected to accelerate progress in this challenging therapeutic area where effective treatments remain limited. Investors can access the latest news and updates relating to CNSP through the company's newsroom at https://ibn.fm/CNSP.

The appointment represents a strategic move for CNS Pharmaceuticals as it seeks to advance its clinical programs and potentially bring new treatment options to patients with brain and central nervous system cancers, conditions that often have poor prognoses and limited therapeutic alternatives. Levin's appointment signals the company's commitment to accelerating development of treatments for these challenging cancers, where crossing the blood-brain barrier remains a significant hurdle in drug development. The transition in leadership comes at a critical juncture as the company advances its most promising drug candidate through clinical development stages.

With brain and central nervous system cancers representing some of the most difficult-to-treat malignancies, the development of effective therapies carries significant importance for patients who currently face limited options. The company's focus on this specialized area of oncology, combined with Levin's extensive industry experience, creates a strategic alignment that could potentially accelerate the path to regulatory approval and patient access. The leadership change reflects the company's recognition of the need for specialized expertise in navigating the complex landscape of oncology drug development, particularly for conditions with high unmet medical need.